CAS: 17852-67-4; (4-(Methylsulfonyl)Phenyl)Hydrazine Hydrochloride

上下游产品

4-methanesulfonylphenylamine 4-bromoohenyl methyl sulfone 5-(4-Fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-3-carboxylic acid ethyl ester 1-(4-methanesulfonylphenyl)-5-phenyl-1H-pyrazole-3-carboxylic acid ethyl ester H-pyrazole-4-carboxylic acid ethyl ester5-(4-fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester

📜4-溴苯甲砜置于potassium Phosphate,Copper(L) Iodide,N,N'-二(2,6-二甲基苯基)草酰胺,十六烷基三甲基溴化铵,一水合肼,盐酸体系中,用 水 用作溶剂,化学反应 0.25H,以0.444 G的收率获得4-(甲基磺酰基)苯肼盐酸盐
参考文献:Cui / Bmpo催化卤代芳烃与水合肼的交叉偶联合成芳族肼
标题:Cui / Bmpo催化卤代芳烃与水合肼的交叉偶联合成芳族肼
摘要:的n,N-双(2,6-二甲基苯基)草酰胺,发现作为一个强大的配体对cu催化的与水合肼芳基卤化物的交叉耦合,从而导致的各种芳基肼的形成在80 ö用c在k 3 Po 4和4 Mol%的十六烷基三甲基溴化铵的帮助下,从芳基溴化物和芳基碘化物中加入水.在大多数情况下,观测到非常好至极好的产量.
Doi:10.1002/cjoc.201800326

专利信息

专利号:US-7442802-B2
优先权日:2002-06-27
标 题:Cyclooxygenase-2 selective inhibitors, compositions and methods of use
发明人：BANDARAGE UPUL K; EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; KHANAPURE SUBHASH P; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.